ProCE Banner Activity

Partnering With Patients With CLL to Make Treatment Decisions in an Evolving Therapeutic Landscape

Clinical Thought
As CLL treatment paradigms continue to shift and become more complex, it is essential to provide patients with education on available treatment options and to engage in open discussions about their care. In this expert commentary, best practices on these concepts are discussed.

Released: November 17, 2021

Expiration: November 16, 2022

Share

Faculty

Jennifer A. Woyach

Jennifer A. Woyach, MD

D. Warren Brown Professor of Leukemia Research
Division of Hematology
The Ohio State University
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Eli Lilly

Janssen Biotech

Pharmacyclics an AbbVie Company

TG Therapeutics

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Jennifer A. Woyach, MD

D. Warren Brown Professor of Leukemia Research
Division of Hematology
The Ohio State University
Columbus, Ohio

Jennifer Woyach, MD, has disclosed that she has received consulting fees from AbbVie, ArQule AstraZeneca, BeiGene, Janssen, MorphoSys, and Pharmacyclics and funds for research support from AbbVie, Karyopharm, Loxo, MorphoSys, and Verastem.